Connor Iapoce

In an interview at ACC 2023, Ankeet Bhatt, MD, describes how virtual care team represents an effective and scalable approach to improve therapeutic optimization across a health system.

In an interview at ACC 2023, Harrington elaborated on the upcoming phase 3 Librexia clinical trial program studying the Factor XIa inhibitor for the prevention of thrombotic events.

An interview with Dr. Annapoorna S. Kini at ACC 2023 breaks down the findings on the effect of evolocumab on coronary plaque characteristics in stable CAD from the YELLOW III study.

Implantation of a pacemaker to enhance exercise heart rate did not improve exercise capacity, symptoms, or exercise cardiac output in patients with HFpEF and chronotropic incompetence in the RAPID-HF trial.

In patients with acute coronary syndrome and multi-vessel heart disease, immediate stent treatment was as safe and effective as staged treatment at one year, according to late-breaking data presented at ACC 2023.

In a Q&A at ACC 2023, Drs. Alexandra Murphy and Birgit Vogel of Mount Sinai discuss sex-specific predictors of MACE and the need for individualization of care to achieve equity in cardiovascular health.

Results from the STOP-CA trial suggest patients taking atorvastatin for one year were significantly less likely to show evidence of heart dysfunction than those who took a placebo.

The TRILUMINATE Pivotal trial reports a reduction in the severity of tricuspid regurgitation with TEER, but no significant difference in survival or hospitalization after one year of follow-up.

A new meta-analysis of 9 randomized trials suggests restricting dietary sodium intake to levels below 2.3 grams per day may increase the risk of death in patients with heart failure.

Results from the NOSTONE trial suggest the incidence of recurrence did not differ among patients receiving hydrochlorothiazide once daily at a dose of 12.5 mg, 25 mg, or 50 mg or once-daily placebo.

Eyes with DRIL were associated with more visual function loss and retinal blood circulation alterations compared to those with subfoveal ellipsoid zone loss only.

Baseline SRF was associated with rapid resolution of macular edema in both DME and RVO, but improvement in visual acuity was associated with SRF only in DME.

Nonacceptance of statin therapy was prevalent among women and could contribute to known sex disparities in the treatment of high cholesterol.

Most trial participants were identified as White and from high-income countries, stressing the need for action from the research community to increase representativeness.

A new analysis suggests the prevalence of myopia among children decreased and mean SER returned to the pre-pandemic levels after the lift of home confinement in China.

The BLA for Regeneron's wet AMD and DME treatment was supported by two pivotal trials demonstrating non-inferior vision gains to aflibercept Injection, with most patients maintaining extended dosing regimens through 48 weeks

A prospective cross-sectional and community-based study from Hong Kong reported statistically significant biomarkers in predicting the risk of lower VA.

Previously known as efanesoctocog alfa, once-weekly ALTUVIIIO™ is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes for adults and children with hemophilia A.

Findings from a recent study indicate a correlation between actual values of visual function and estimated values with a deep learning model using ultra-widefield FAF images.

An analysis of data from AREDS2 suggests extramacular drusen in eyes with AMD are more frequent with an increased drusen burden within the macula.

The historic FDA approval of pegcetacoplan marks the first and only approved treatment for geographic atrophy. In a new interview, Dr. Wykoff expresses what approval means for patients with the debilitating disease.

Although the use of β-Blockers did not affect early-stage AMD, their long-term use was indicated to be protective against the risk of AMD among patients with hypertension.

The FDA assigned a PDUFA date of September 28, 2023 for the phentolamine ophthalmic solution 0.75%.

A new study indicates that OCTA-derived features of MNV disease activity may be useful biomarkers to confirm MNV stability in patients with treated stable nAMD.

A 0.18-mg implant may be an effective option in managing noninfectious uveitis affecting the posterior segment.

Baseline evidence of deep capillary nonperfusion in eyes with clinically referable NPDR may predict short-term complications with high accuracy.

Investigators stress the need for timely surgical intervention to ensure favorable visual outcomes in patients with severe complications, including retinal detachment and vitreous hemorrhage.

Investigators from the University of Pennsylvania suggest the associations, particularly beta peripapillary atrophy, and tilted optic discs, should be accounted for when investigating glaucoma in high-risk black populations.

The therapy is the first and only FDA-approved treatment for geographic atrophy, with approval based on positive results from the phase 3 DERBY and OAKS trials.

The NDA has been granted Priority Review with a PDUFA goal date of August 19, 2023. The FDA is not currently planning to hold an Advisory Committee meeting.